Axsome Therapeutics

AXSM · NASDAQ

$159.58+$3.77 (+2.42%)TodayMarket closed · Oct 20, 7:46 PM ET

Prev close $155.81

Latest news

Press releaseOct 7, 7:00 AM ETGlobe Newswire
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
NewsSep 25, 4:19 PM ETChandrima Sanyal
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
NewsSep 23, 1:35 PM ET
10 Health Care Stocks Whale Activity In Today’s Session
Press releaseSep 21, 7:00 AM ETGlobe Newswire
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
NewsSep 21, 5:34 AM ETAvi Kapoor
5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In
Press releaseSep 17, 7:00 AM ETGlobe Newswire
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
Press releaseSep 2, 7:00 AM ETGlobe Newswire
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Press releaseAug 31, 7:00 AM ETGlobe Newswire
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
NewsAug 11, 10:30 AM ETAvi Kapoor
Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results
Press releaseAug 10, 7:00 AM ETGlobe Newswire
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Press releaseJul 15, 7:00 AM ETGlobe Newswire
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
Press releaseJul 14, 7:00 AM ETGlobe Newswire
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
NewsJul 8, 1:35 PM ET
9 Health Care Stocks Whale Activity In Today’s Session
Press releaseJul 7, 7:00 AM ETGlobe Newswire
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
NewsMay 4, 9:54 AM ETAvi Kapoor
Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday
NewsMay 4, 9:24 AM ET
Axsome Therapeutics Q1 2026 Earnings Call: Complete Transcript
NewsMay 4, 8:18 AM ETVandana Singh
Strong Drug Sales Lift Axsome Revenue, But Profit Miss Drags Stock
NewsMay 4, 7:11 AM ET
Earnings Scheduled For May 4, 2026
NewsMay 1, 8:49 AM ETVandana Singh
Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression
Press releaseMay 1, 7:15 AM ETGlobe Newswire
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
NewsApr 1, 1:36 PM ETVandana Singh
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda
Press releaseMar 12, 10:26 AM ETGlobe Newswire
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)
Press releaseFeb 26, 12:07 PM ETPRNewswire
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
NewsFeb 23, 9:01 AM ET
Beyond The Numbers: 11 Analysts Discuss Axsome Therapeutics Stock
NewsFeb 23, 6:11 AM ET
Earnings Scheduled For February 23, 2026
NewsFeb 20, 12:01 PM ET
Axsome Therapeutics's Earnings Outlook
NewsFeb 17, 2:32 PM ETVandana Singh
Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment
Press releaseFeb 5, 10:47 AM ETGlobe Newswire
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)
NewsJan 20, 7:00 AM ET
Expert Outlook: Axsome Therapeutics Through The Eyes Of 14 Analysts
NewsDec 31, 12:40 PM ETAvi Kapoor
Why FuelCell Energy Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
NewsDec 31, 10:30 AM ETVandana Singh
FDA Fast-Tracks Axsome's Alzheimer's Agitation Drug, Stock Soars
NewsDec 31, 10:12 AM ETAvi Kapoor
Axsome Therapeutics, Plug Power And Other Big Stocks Moving Higher On Wednesday
NewsOct 31, 2:01 PM ET
Uncovering Potential: Axsome Therapeutics's Earnings Preview
Press releaseOct 24, 11:20 AM ETBusiness Wire
Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Press releaseSep 12, 8:12 PM ETGlobe Newswire
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm
NewsAug 18, 9:45 AM ETVandana Singh
Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years
Press releaseJun 4, 7:00 PM ETGlobe Newswire
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm
Press releaseMay 14, 6:30 PM ETGlobe Newswire
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm
Press releaseMay 1, 7:00 AM ETGlobe Newswire
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
Press releaseApr 9, 7:05 PM ETGlobe Newswire
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm
Press releaseApr 8, 2:03 PM ETPRNewswire
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm
NewsApr 7, 11:38 AM ETAvi Kapoor
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
NewsMar 25, 11:02 AM ETVandana Singh
Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal
NewsFeb 18, 12:47 PM ETErica Kollmann
US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday?
Press releaseJan 31, 7:00 AM ETGlobe Newswire
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
Press releaseAug 10, 9:00 PM ETGlobe Newswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NewsAug 6, 10:06 AM ETAvi Kapoor
Lithia Motors To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday
Press releaseJul 25, 8:30 AM ETGlobe Newswire
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
NewsJul 24, 9:25 AM ETAvi Kapoor
Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible'

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach

10 Health Care Stocks Whale Activity In Today’s Session

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

9 Health Care Stocks Whale Activity In Today’s Session

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday

Axsome Therapeutics Q1 2026 Earnings Call: Complete Transcript

Strong Drug Sales Lift Axsome Revenue, But Profit Miss Drags Stock

Earnings Scheduled For May 4, 2026

Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression

Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader

Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)

Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders

Beyond The Numbers: 11 Analysts Discuss Axsome Therapeutics Stock

Earnings Scheduled For February 23, 2026

Axsome Therapeutics's Earnings Outlook

Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)

Expert Outlook: Axsome Therapeutics Through The Eyes Of 14 Analysts

Why FuelCell Energy Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

FDA Fast-Tracks Axsome's Alzheimer's Agitation Drug, Stock Soars

Axsome Therapeutics, Plug Power And Other Big Stocks Moving Higher On Wednesday

Uncovering Potential: Axsome Therapeutics's Earnings Preview

Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm

Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years

Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm

Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm

Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm

This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal

US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday?

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Lithia Motors To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday

Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected

Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible'